BiondVax to Present at BIO-Europe Spring
<!-- Name:DistributionId Value:8790089 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Browsing Tag
$BVXV
BiondVax Presenting at BIO CEO & Investor Conference
<!-- Name:DistributionId Value:8741991 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
BiondVax’s Innovative Inhaled Anti-SARS-CoV-2 NanoAb Virtually Prevented Illness When…
COVID-19 illness was virtually prevented in hamsters administered BiondVax’s inhaled NanoAb and infected three hours later with SARS-CoV-2 Data further strengthens value proposition of…
BiondVax’s Innovative Inhaled COVID-19 Therapy Virtually Eliminated SARS-COV-2 Virus…
Hamsters infected with SARS-COV-2 and then treated with BiondVax’s inhaled anti-COVID-19 nanosized antibodies (NanoAbs) had over 30-times lower lung viral titer on average compared to those…
BiondVax CEO Issues Letter to Shareholders
JERUSALEM, Dec. 30, 2022 (GLOBE NEWSWIRE) -- via InvestorWire – BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biotechnology company focused on developing, manufacturing and…
BiondVax reports successful results in preclinical in vivo study of its innovative…
Hamsters infected with SARS-COV-2 and then treated with inhaled anti-COVID-19 NanoAbs demonstrated significantly less severe illness and faster recovery in comparison to infected hamsters…